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PyrazinamideIt has been widely accepted, that pyrazinamide (PZA) resistance in Mycobacterium tuberculosis is corre-
lated with mutations in the pncA gene. But since years researchers have been puzzled by the fact that
up to 30% of PZA resistant strains do not show any correlation between PZA resistance and mutations
in the pncA gene, and thus may vary with geographic area. The objective of the study was to investigate
the correlation between PZA susceptibility and mutations in pncA gene in M. tuberculosis isolates from
individuals living in a highly endemic area. Therefore we analyzed drug resistant and multidrug resistant
(MDR) isolates from patients in Rio de Janeiro, Brazil. From a total of 97 clinical isolates of M. tuberculosis
35 were identiﬁed as PZA resistant, 24/35 strains did not show PZase activity and 15/24 (62.5%) strains
possess mutation in the pncA gene. This is a low correlation between PZA resistance and PZase activity
(68.6%) and even lower correlation between PZA resistance and the presence of mutation in pncA gene
(45.7%). Most of the mutations found were conserved near the active site or metal binding site of PZase.
The 146A > C mutation was found both in PZA resistant and susceptible isolates, suggesting that this
mutation may not fully associated with PZA resistance. Of the mutations found, three have not been pre-
viously described. The insertions 192–193 TCCTCGTC and 388–389 AGGTCGATG, although found before,
here was found to be a short tandem repeat and in one strain, insertion of the IS6110 was observed 55 nt
upstream of the gene. All PZA resistant isolates had no mutation in the gene coding ribosomal protein S1
(rpsA), which has recently been proposed as alternate target for pyrazinoic acid (POA). The results show a
low association of PZA resistance and pncA gene mutations in a selected patient group from an highly
endemic area. Our ﬁndings point out that the phenotypic susceptibility testing remains important for
the detection of PZA-resistant M. tuberculosis.
 2013 Elsevier B.V. All rights reserved.1. Introduction
Tuberculosis (TB) still remains one of the leading causes of mor-
bidity and mortality in the world. At present one-third of the
world’s population is infected with Mycobacterium tuberculosis,
the causative agent of TB. In 2011, 1 million people HIV negative
and four-hundred and thirty thousand HIV positive died from the
disease, 8.7 million new cases are estimated, of which 13% are
coinfected with HIV (WHO, 2012).Pyrazinamide (PZA) is a ﬁrst-line oral agent for TB short course
chemotherapy. It is one of the few anti-TB drugs effective against
persistent tubercle bacilli. It is only active against M. tuberculosis
andMycobacterium africanum in the host, whileMycobacterium bo-
vis is inherently resistant to it. Since the global resurgence of drug
resistant TB strains, an increasing number of PZA resistant strains
have been observed. PZA is a prodrug which is converted into the
active substance pyrazinoic acid (POA) by M. tuberculosis at low
pH medium (Hewlett et al., 1995; Mc Dermott and Tompsett,
1954; Tarshis and Weed, 1953).
In M. tuberculosis PZA is converted to POA by a 19.6 kDa pyr-
azinamidase (Rv2043c), encoded by pncA, a gene which spans
561 base pairs (Blanchard, 1996). PZA susceptible M. tuberculosis
possesses a functional PZase, and mutations in this gene have
been reported leading to reduction or complete loss of PZase
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and Kilburn, 1983; McClatchy et al., 1981). Despite a majority
(70–97%) of PZA-resistant isolates of M. tuberculosis exhibit muta-
tions in their pncA gene or putative regulatory region, PZA resis-
tant isolates with PZase activity and wild type pncA sequences
have also been reported in several studies, indicating the exis-
tence of alternate molecular mechanism of PZA-resistance (Ngo
et al., 2007; Raynaud et al., 1999; Zhang and Mitchison, 2003).
Recently the 30S ribosomal protein S1 (rpsA) was found to bind
to POA and subsequently inhibiting trans–translation. Mutations
in the rpsA gene were associated with PZA resistance in clinical
isolates without mutations in pncA (Shi et al., 2011). We studied
the relation between PZA resistance, PZase activity and mutations
in pncA and or rpsA in clinical strains isolated from TB patients in
a highly endemic area of Brazil, Rio de Janeiro state (57.6/100.000
inhab).2. Materials and methods
2.1. Clinical strains and identiﬁcation
A total of 97M. tuberculosis clinical strains were exclusively iso-
lated from sputum samples collected from patients who were diag-
nosed with susceptible or resistant TB attended at University
Hospital Clementino Fraga Filho, and Hospital Municipal Raphael
de Paula Souza, Rio de Janeiro, Brazil between 2003 and 2005. Uni-
versity Hospital Clementino Fraga Filho is a tertiary care hospital
that attends patients with TB and co-morbidities including sero-
positive HIV and has no spontaneous demand. Hospital Municipal
Raphael de Paula Freitas is a reference center for MDR-TB cases.
The clinical specimens were treated with N-acetyl-L-cysteine-
NaOH and 0.2 ml of the pellets was inoculated in tubes with
Löwenstein–Jensen (LJ) medium. The genus Mycobacterium was
conﬁrmed by Ziehl–Neelsen staining and as M. tuberculosis com-
plex by biochemical tests such as: nitrate reduction, niacin produc-
tion and catalase activity ().Table 1
Primers for pncA and rpsA used in the study.
Name Primer sequence 50 ? 30 Description
pncA-F CGGCGTCATGGACCCTATA Ampliﬁcation and sequencing of
pncA
pncA-R GAACCCACCGGGTCTTCG Ampliﬁcation and sequencing of
pncA
pncA-sf1 CATTGCGTCAGCCGTACT Sequencing of pncA
pncA-sf2 CCACCGATCATTGTGTGC Sequencing of pncA
pncA-sr1 GCAGCCAATTCAGCAGTG Sequencing of pncA
pncA-sr2 GGTCGATGTGGAAGTCCT Sequencing of pncA
Rv2044cF TGGCGAATTGAACCTTTTCT Ampliﬁcation and sequencing of
454 nt upstream of pncA
Rv2044cR CACCCTCGCAGAAGTCGT Ampliﬁcation and sequencing of
454 nt upstream of pncA
Transp-sf ACCGAAGAATCCGCTGAG Sequencing of IS6110
Transp-sr TCGCGTCGAGGACCATGGA Sequencing of IS6110
rpsA-F CGATTTTTCCGCCCTGAGT Ampliﬁcation and sequencing of
rpsA
rpsA-R ACGTGAACGCGATCAGCTG Ampliﬁcation and sequencing of
rpsA
rpsA_sf1 ACATCGGGCTGCGCGGTTTCC Sequencing of rpsA
rpsA_sf2 AGCGTCACGTCGAGGTGC Sequencing of rpsA
rpsA_sr1 ACTTGGTGACCTTGCCCG Sequencing of rpsA
rpsA_sr2 TTGAGCGCCTCGATGGTGC Sequencing of rpsA2.2. Drug susceptibility testing and PZase activity assay
TheM. tuberculosis isolates were tested for PZA susceptibility by
proportion method in LJ medium pH 5.5–5.8 with PZA at 100 lg/ml
(Singh et al., 2007). In addition the isolates were tested for strepto-
mycin (STM), isoniazid (INH), ethambutol (EMB) and rifampicin
(RPM) susceptibility using the standard proportion method on LJ
medium. An isolate was deﬁned as resistant when the percentage
of colonies exceeded 1% of the growth on a drug-free medium
(control) at the critical concentrations of 4, 0.2, 2, and 40 lg/mL,
respectively (Canetti et al., 1969). Multidrug resistance (MDR) is
deﬁned as resistance to at least INH and RMP, resistance to two
or more drugs but not to MDR was assigned as drug resistance,
and resistance to any one drug as monoresistant. PZase activity
was determined using a modiﬁed method described by Wayne
(Wayne, 1974). In brief, a heavy loopful of mycobacterial culture
freshly grown on LJ medium was inoculated in two 16  125 mm
glass tubes with screw cap containing 5 ml Dubos broth medium
supplemented with 100 lg/ml PZA and 2 mg/ml sodium pyruvate.
After incubation at 37 C for 4 or 7 days (when negative at the
fourth day the second tube was incubated for three more days),
1 ml of freshly prepared 1% ferrous ammonium sulphate solution
was added to each tube, and the presence of a pink band was as-
sessed. M. tuberculosis H37Rv and Mycobacterium fortuitum were
used as a positive and negative control, respectively for the assay.
Strains giving discordant results in phenotypic and genotypic anal-
ysis were retested for PZA susceptibility (proportion method andBACTEC Mycobacteria Growth Indicator Tube (MGIT), as recom-
mended by Bencton Dickinson) and PZase activity.
2.3. DNA isolation
Chromosomal DNA was isolated as described by van Embden
et al. (1993) from a loopful of clearly visible mycobacterial fresh
growth in LJ. The puriﬁed DNA was dissolved in 20 ll of 0.1  TE
buffer and stored at 20C until used. DNA concentration was de-
ﬁned using a spectrophotometer Nanodrop 1000 (ThermoScientif-
ic, USA).
2.4. PCR and sequencing
The gene pncAwas ampliﬁed with the pair of primer pncA-F and
pncA-R which produced 772 nt fragment. This included 81 nt up-
stream of pncA and 130 nt downstream the gene. The PCR was
done in a MJ Research PTC-200 thermo cycler (Harlow Scientiﬁc,
Arlington, MA) with 10 lM of forward and reverse PCR primers,
200 lM dNTP, 1.5 mM MgCl2, 1X Qiagen PCR Buffer and 0.5 U
Taq DNA Polymerase (Qiagen Master Mix, Qiagen, Germany) using
0.02–0.04 lg of genomic DNA in a total volume of 20 ll. PCR con-
ditions used was an initial denaturation at 95 C for 10 min; fol-
lowed by 30 cycles of sequentially denaturation at 95 C for 30 s,
annealing at 57 C for 30 s and polymerization at 72 C for 50 s.
The ﬁnal annealing was done at 95 C for 10 min. Sequencing of
pncA was done with the primers pncA-F, pncA-R, pncA-sf1, pncA-
sf2, pncA-sr1, pncA-sr2. For the detailed analysis of the pncA pro-
moter region and additional 454 nucleotides upstream pncA, the
primers Rv2044cF and Rv2044cR were used for ampliﬁcation and
sequencing. The PCR was carried out as described for pncA except
30 s were used for the extension step. The IS element of strain
number 13 was analyzed with the primers Transp-sf and Transp-
sr. All primers which were used for ampliﬁcation and sequencing
of pncA are summarized in Table 1 and Fig. 1.
Sequencing of rpsAwas done with the primers rpsA-F and rpsA-
R (Table 1). The 1600 nt PCR product, included 130 nt upstream of
the gene. RpsA was ampliﬁed with BioMix (Bioline GmbH, Ger-
many). The PCR was performed as described for pncA except
100 s were used for elongation. The PCR products were puriﬁed
with a QIAquick PCR puriﬁcation kit (Qiagen GmbH, Hilden,
Germany).
Fig. 1. Depiction of the pncA gene and the position of the identiﬁed point mutations and insertions in this study. Sequencing primers are shown as short white arrows, PCR
primers as short black arrows. The positions of triplets, coding for the residues of the metal binding site and substrate binding site are shown as striped and black boxes,
respectively.
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Automated 3730xl DNA Analyzer (Applied Biosystems, Inc, USA)
using the same PCR primer set and sequencing primers (Table 1).
The DNA sequences were analyzed by comparison with reference
strain M. tuberculosis H37Rv DNA sequence using Pregap version
1.6 and Gap4 version 4.11 of Staden Package (Staden et al.,
2000). Mutations comparison was performed by searching in the
TB Drug Resistance Mutation Data Base (Sandgren et al., 2009;
http://www.tbdreamdb.com/PZA_Rv2043c_HighConﬁdenceMuta-
tions.html).3. Results
3.1. Characteristics of isolates, PZA-susceptibility, and mutations in the
pncA gene
A total of 97 M. tuberculosis clinical isolates were analyzed for
PZA-susceptibility, PZase activity and mutation in pncA gene.
Sixty-two isolates were pyrazinamide susceptible and 35 were
pyrazinamide-resistant. Twenty-two of the 35 pyrazinamide-resis-
tant (PZAR) strains were MDR (63%). From the 13 non-MDR strains
were four strains PZA mono-resistant. In addition to the PZA resis-
tance were two strains resistant to INH. Three strains were resis-
tant to INH and STM. There were three single strains resistant to
EMB + RMP, STM + EMB, and INH + EMB. Sixty-two isolates were
pyrazinamide susceptible (PZAS), of which 38 were pan susceptible
(61.3%) to all four assayed drugs and 10 were mono-resistant to
any one of the four drugs (16.1%) and seven were MDR (11.3%).
Seventeen PZAS strains (25.8%) were resistant to STM and EMB in
different combinations.
In 24 out of 35 PZAR isolates (68.6%) we could not detect PZase
activity. This is a low correlation related to other studies, however
similar (65.4%) found in Thailand (Jonmalung, 2010). Sixteen of
these 35 PZAR strains possessed mutation in the pncA gene
(45.7%), and 62.5% of PZase-negative strains possessed a mutation
in the pncA gene, however concordance for all tests was 42.8%
(Table 2).Table 2
Summary of pyrazinamide (PZA) susceptibility, PZase activity and changes in pncA observ
Total Strains: 97
PZA susceptible strains: 62
PZase + : 50 PZase  : 12
Wild type Mutant Wild type Mutant
46 4 12 0
PZase +/: pyrazinamidase positive/negative.3.2. Distribution of mutations in the pncA gene
Among the studied strains the mutations in pncA were distrib-
uted throughout the gene as in previous studies (Barco et al.,
2006; Lemaitre et al., 1999; Raynaud et al., 1999; Singh et al.,
2007; Somoskovi et al., 2007). Point mutations were observed in
14 strains, causing amino acid substitutions, which are located
near the active site or metal binding site (active site: V7; metal
site: D49, C72, T76) (Lemaitre et al., 1999; McClatchy et al.,
1981; Scorpio et al., 1997; Somoskovi et al., 2007; Zhang and
Mitchison, 2003). Other isolates bearing different mutations at po-
sition 49 showed PZA-susceptibility as well as PZA-resistance. For
example, isolates identiﬁed by the numbers n# 25, 37 and 47 have
a D49A mutation in the pncA gene but show a contrasting pheno-
type concerning PZA susceptibility (Table 3). Such contrasting re-
sults for strains bearing a mutation near the active site were also
encountered in previous studies (Dormandy et al., 2007; Hirano
et al., 1997; Somoskovi et al., 2007; Sreevatsan et al., 1997). Struc-
ture of PZase recently published showed the aspartic acid at posi-
tion 49 binds directly to the metal in the enzyme (Petrella et al.,
2011). A summary of all observed mutations is shown in Fig. 1.
None of the analyzed strains hadmutation in putative promoter re-
gion of pncA. Even up to 454 nt upstream of pncAmutation was not
observed (data not shown).3.3. Insertions and analysis of IS6110
In ﬁve strains 8, 2 and 9 nt insertions (TCCTCGTC, CG, AGGTC-
GATG) were observed between position 192–193, 444–445 and
388–389, respectively. The 8–9 nt inserts TCCTCGTC and AGGTC-
GATG produced a short tandem repeat of (AGGTCGATG)2 and
(TCCTCGTC)2 in pncA gene, respectively (Fig. 1). The 9 nt insertion
in codon 130 led to deletion of V130 and insertion of additional
three amino acids. Though the insertion AGGTCGATG between
positions 388–389 was previously reported (Sreevatsan et al.,
1997) it was not known to produce tandem repeat as is being re-
ported now. These repeats are very likely remains of a mobile ele-ed in the clinical M. tuberculosis isolates.
PZA resistant strains: 35
PZase +: 11 PZase  : 24
Wild type Mutant Wild type Mutant
10 1 9 15
Table 3
pncA gene mutations detected in clinical M. tuberculosis isolates.
Strain No PZA susceptibility# PZase activity§ Amino acid change Mutation
Point mutation
103 R  V 7 G 20 T > G
92 R  L 35 P 104 T > G
37 S + D 49 A 146 A > C
47 R  D 49 A 146 A > C
25 R  D 49 A 146 A > C
13/04 S + D 49 E 147 C > G
36 R  P 69 A 205 C > G
82 R  C 72 R 214 T > C
41 R  C 72 Y 215 G > A
107 R  T 76 P 226 A > C
4 R  T 76 I 227 C > T
20 R  L 158 P 457 C > G*
23 R  L 172 P 515 T > C
66 R  M 174 V 523 A > G
Insertion
26 R  Frameshift 192–193 TCCTCGTC*
101 R  Frameshift 192–193 TCCTCGTC*
32 R  Frameshift 192–193 TCCTCGTC*
89 R  V 130EVD 388–389 AGGTCGATG
40 R  Frameshift 444–455 CG*
Deletion
33 R  172-173 Deletion 2 nt *
Insertion Elements
13 S + IS6110 at 55 nt*
PZA: pyrazinamide. PZase +/: pyrazinamidase positive/negative.
# R: resistant, S: susceptible.
§ +: active, : inactive,
* Unreported mutation, insertion, or deletion.
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IS6110 located 55 nt upstream of the pncA gene (this study) and
presence of disrupting pncA (Lemaitre et al., 1999).
3.4. Mutational analysis of the rpsA gene
None of the PZA-resistant strains harbored mutations in the
rpsA gene.
4. Discussion
PZA resistance has been correlated with mutations in pncA gene,
which codes for a pyrazinamidase, converting the prodrug PZA into
POA. Correlation of drug resistance with a defect in a speciﬁc ‘‘drug
resistant’’ gene is observed for several drugs. Resistance against
oﬂoxacin, rifampicin, ethambutol, and isoniazid show variable cor-
relation between the drug resistance phenotype and mutations in
the drug resistance genes gyrA (75–94%), rpoB (90–95%), embB
(47–65%), and katG (31–97%) /inhA (8–43%), respectivand
(TCCTCGTC)ely (Zhang and Yew, 2009).
In several studies the correlation of PZA resistance and muta-
tion in pncA has also been reported in a variety of low range
(41–80%) (Bishop et al., 2001; Huang et al., 2003; Miyagi et al.,
2004; Rodrigues et al., 2005; Chan et al., 2007; Pandey et al.,
2009; Jonmalung et al., 2010). While in other the correlation has
been reported higher such in South Africa (91–92%) (Louw et al.,
2006; Mphahlele et al., 2008), China (91%) (Hou et al., 2000), Japan
(97%) (Hirano et al., 1997), S. Korea (97%) (Lee et al., 2001). In the
studied strains, only a correlation of 45.7% between PZA resistance
and pncA mutation was observed which is far lower than the
majority studies performed so far, including reports from low en-
demic area in Brazil (72% and 84%) (Rodrigues et al., 2005; Barco
et al., 2006), although similarly found in South Africa (67%) and
Taiwan (41%) (Bishop et al., 2001; Huang et al., 2003). Such a lowercorrelation might be attributed to some extend due to the limita-
tion of phenotypic susceptibility test based on LJ proportion which
was done at pH 5.5–5.8 with 100 lg/ml PZA. False resistance is the
most common cause of error in the results of susceptibility testing
to PZA, and recently Simons et al. (2012) reported that this occurs
under the inﬂuence of inoculum. The ammonia produced by bacte-
rial metabolism lead to increases the pH of the culture medium
and hence inactivation of the drug (Mc Dermott and Tompsett,
1954; Zhang et al., 2002). However susceptibility testing was re-
peated carefully, including using MGIT for same discordant strains.
The limitation of the test is not the sole reason for contribution of
low correlation between PZA resistance and pncA mutation is sup-
ported by the presence of strains which were resistant depending
on concentration of PZA used (Dormandy et al., 2007).
On the other hand, it is important to note that most of these
strains are drug resistant or MDR and according to several authors
resistance to PZA is associated with strains harboring multiple
resistance to the ﬁrst line drugs (>49%), (Chang et al., 2011; Chiu
et al., 2011; Fonseca et al., 2012; Kim et al., 2012; Louw et al.,
2006; Minime-Lingoupou et al., 2010; Mphahlele et al., 2008; She-
nai et al., 2009). Frequency in pncA mutation among MDR strains
was similar found in S. Korea (56.2  63.9%). So, it must have a rea-
sonable explanation of the presence of these complex patterns
which are most probably not a result of a defect in a single gene.
The mutation found was diverse and scattered along the gene.
Mutation is not always associated with resistance as described
here and by other Jonmalung et al. (2010).
As the PZA susceptibility and pncA mutation were not highly
correlated in the current studies, we also sequenced rpsA, which
codes for the ribosomal protein S1, which has been reported as
additional target for PZA resistance (Shi et al., 2011). None of the
resistant strains had a mutation in the rpsA gene. Recent study
on analyze of PZAR strains reported rpsA gene has no impact on
PZA resistance, although authors have found few mutations could
S. Bhuju et al. / Infection, Genetics and Evolution 19 (2013) 1–6 5not clearly associate with strains phenotypes (Alexander et al.,
2012).
The results show a low association of PZA resistance with muta-
tions in the pncA gene in isolates from patients living in a highly
endemic area. The results jeopardize the use of methods which
use pncA as sole indicator for the detection of PZA resistance. These
informations may be helpful in the TB clinical practice for the
selection and interpretation of diagnostic tests.
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